delivering Jeff. a the to globally. we continued precision progress therapies our goal fourth Good In quarter, to morning, patients portfolio everyone. Thanks, make toward of of
launch With have marketing SM importantly, set of in RET-altered the Europe the foundation of as most the GIST thyroid two of AYVAKIT growth. cancer, for in we year, the the as drivers to The a and PDGFR-alpha the launch AYVAKIT be in most ongoing well well, year submission European half the U.S. a SM in the in FDA first anticipated XXXX Germany, will for for GAVRETO be of growth of that now U.S., our applications GAVRETO as significant advanced of the important for of U.S. and approval first launch advanced AYVAKIT of for in
let had million the near-term. sales of set to for in with bringing approval revenue million, late the our $X.X primarily thyroid quarter we product GAVRETO have results total XXXX were net for to the pleased quarter to for in SM, was fourth driven $XX.X by across the thereby the turning Revenue revenue revenues in in launch quarter, GAVRETO. of fully Before me to million. receive product also indications we recognized million And GAVRETO and start expect $X launch. enabling to AYVAKIT. fourth in cancer $X.X We We us
GAVRETO ago, and available should weeks patients indication. these we seen cancer which patients. awareness inhibitor further two Overall, GAVRETO we have for one-third carcinoma, approximately market RET the addition, to thyroid create thyroid guidelines of papillary of are to-date, was medullary treatment and for this NCCN have comprise selective the added excited to In
two Genentech areas. of at the with we continue As to in launch key advance focusing we are partners GAVRETO, our
a we progress to since starting realize good first RET selective potential inhibitor, treated longer our December; The of increasing of where is inhibitor, second the to seen term of which RET selective the number GAVRETO. are identified share the be overall enable will key with patients, is RET us growing have who and on patients a
start with of patient share me our Let new starts.
Following the patients, our share on of a thyroid December, kicked-up in for cancer selective new approval GAVRETO XX%. inhibitor starting about to RET
for We were are fourth community inhibitor majority first of the mix selective prescribers in balanced RET prescribing seeing generally a and the academic prescribers, of commercially and time. quarter GAVRETO the a
increase patient is indicator a starts, of expect revenue we leading duration be clinical new We continuing on combined of the on our will key growth. studies, with therapy share focused prolonged our to when this metric, of as based
predictable manageable to encouraged We daily GAVRETO's safety once which healthcare from and convenient on continue durable by profile and differentiated be profile, and very feedback payers providers deep dosing. responses, a includes and
visits inhibitor, are second patients with RET patients area starting treatment. focus of a of on approximately key as that year. the cancer market in was been in cancer all the shown right and of around impact a here, the the we on is Our as rebounding the U.S., RET Data of impacted two initiation now clinic well is selective RET the overall care having COVID biomarker the COVID. testing have from who drivers of identified increasing RET patients XX% for versus volume the see to comprehensive as are testing XX%. is of the patients of public treated selective this prior by estimate have number biomarker We well earlier increasing positive which as inhibitor percent domain There as lower rates in in in QX
will these We expect diagnosed the approach we half number impacts patients see of subside rebound. and we as that the of XXXX, newly second
effective with can rapidly identification plays testing patients with will of educational their addition, our increase with who efforts driving we market the biomarkers, that identified total will treated. where availability portfolio is of targeted Overall, and combined In therapy we an the as which percent efforts complement a opportunity partnership lung role. key patient have targeted for growth. efforts GAVRETO other anticipate Genentech are and expand, therapies amplify a of area This seen highly the be identification patient another driver across significant Their team. our RET the of of and
AYVAKIT, PDGFR-alpha growth past initiated And therapy our quarters. the additional approach, in seen fourth the first U.S. few we our starts to Germany country with launch total quarter. patient first consistent over GIST. patients We've the targeted in Europe, on now In country incremental and in seeing new consistent with anticipate launches. over Turning in we time
anticipated on potential Of milestone opportunity This primary U.S. launch mastocytosis focus second AYVAKIT of as late course, systemic portfolio. a first stage the in the steps largest critical advanced in towards in our quarter. the we take realizing be for for will preparing Blueprint the commercial the our is
major be majority our all opportunity X% about of patients only about SM the us centers. half This represent While an gives SM hematology U.S. overall of to efforts advanced SM advanced XX at these the tend focus patients patients treat of XX% the centers about that to on population, in treated educational to
with I in mind. built organization our As commercial the portfolio we’ve previously, said
side existing to who meet be the So, we identify our of will infrastructure SM of advanced the patients and to treated flex leveraging main launch, largely adapt may footprint our portfolio needs these centers. including
to are forward potential non-advanced for beginning XXXX SM larger in AYVAKIT the population. We think a to also launch
widely making for testing. We priority KIT the and patients. is testing near-term here driver actionable mutation, remove SM increase DXXXV, identification diagnosis available, to will help barriers for to clear patient SM Our with that accessible believe blood-based non-advanced
testing closely now blood-based these has in medicine part been working States. precision in with available And sensitive commercially efforts, Our testing United providers. team highly the is to due
course labs, cover in to of of the grow about We XX% the of expect to SM testing availability this over patients year which U.S.
SM that diagnosed the disease access patients to are other increased testing, with number of and efforts, treatment. will are confident education increase have who combined and We
building the value opportunity Anchored our SM, significantly into on will while is of who worldwide. our the bringing to impact are opportunities the our will ongoing call patients promise for near-term by planned turn Development, significant that our we to R&D efforts. Blueprint I'll Fouad? President course see the Research of we Fouad, portfolio over foundation more now accelerating the expand the portfolio launches, XXXX, & Over address. with the and I commercial early-stage detail of provide translating poised in the to
